The specific plan and treatment schedule of axitinib (Inlida) for the treatment of renal cancer

Axitinib is an oral small molecule tyrosine kinase inhibitor (TKI) that mainly acts on VEGFR1, 2, 3, inhibiting tumor angiogenesis, thereby preventing tumor growth and metastasis. It is indicated for patients with advanced or metastatic clear cell renal cell carcinoma who still require effective anti-tumor intervention after failure of first- or second-line therapy. Clinical studies have shown that axitinib can significantly prolong progression-free survival and improve some symptoms of patients.

The standard dose is5 mg taken orally twice daily with or without food. During treatment, the dose needs to be adjusted according to the patient's blood pressure, liver and kidney function, and tolerance. If blood pressure is elevated, antihypertensive drugs can be used first. For those with severe elevation or poor tolerance, the dose can be temporarily reduced to 3 mg twice a day. Patients with abnormal liver function need to be closely monitored, and if necessary, adjust the dose or temporarily discontinue the drug.

Axitinib generally adopts the mode of continuous oral administration and periodic evaluation. The initial treatment lasts for approximately 4–8 weeks as an evaluation cycle, and tumor changes are monitored through imaging examinations. If the efficacy is obvious and well tolerated, the original dose can be maintained until disease progression or intolerable side effects occur. During treatment, blood pressure, blood routine, and liver and kidney function need to be monitored monthly to ensure safe medication use.

During the treatment period, patients should regularly review imaging and laboratory indicators, and pay attention to lifestyle interventions, such as low-salt diet, regular exercise, and cardiovascular risk control. Avoid simultaneous use with potent CYP3A4 inhibitors or inducers to prevent abnormal blood concentration. When high blood pressure, proteinuria, rash on hands and feet or gastrointestinal reactions occur, timely feedback should be reported to the doctor to adjust the dosage or treat symptoms to ensure efficacy and safety.

Reference materials:https://www.drugs.com/